Effects of synthetic oligonucleotides on human complement and coagulation

Biochemical Pharmacology
D R ShawS Agrawal

Abstract

Oligodeoxynucleotide phosphorothioates (PS-oligos) are being studied as novel therapeutic agents based on their ability to inhibit gene expression. Preclinical studies produced unanticipated complement and coagulation effects in monkeys receiving high-dose PS-oligo. In the present in vitro studies, PS-oligo inhibited normal human blood clotting as well as subsequent assays for prothrombin fragment PF(1+2) and hemolytic complement. PS-oligo treatment of normal donor plasma produced concentration-dependent prolongations of clotting times, with the activated partial thromboplastin time more sensitive than prothrombin time or thrombin clotting time. PS-oligo treatment of normal donor serum similarly reduced hemolytic complement activity in a concentration-dependent manner. Reduced hemolysis correlated with increased levels of complement fragment C4d. The anti-heparin drug protamine sulfate inhibited in vitro effects of PS-oligo in both complement and coagulation assays, suggesting that charged residues in internucleotide linkages of PS-oligo mediated the observed activities. Therefore, oligonucleotides with varying internucleotide linkages, nucleotide sequence, or secondary structure were compared. Both complement and coagulation e...Continue Reading

References

Sep 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalJ Y Tang
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalT Pederson
Sep 1, 1982·Molecular Immunology·M R Van Schravendijk, R A Dwek
Jan 1, 1995·Antisense Research and Development·S K SrinivasanP L Iversen
Apr 6, 1995·Nature·A M KriegD M Klinman
Jan 1, 1995·Clinical Pharmacokinetics·S AgrawalJ Tang
Jan 1, 1994·Antisense Research and Development·A A PadmapriyaS Agrawal
Feb 1, 1995·Current Opinion in Biotechnology·S Agrawal, R P Iyer
Dec 1, 1994·Clinical Pharmacology and Therapeutics·S T CrookeW H Barr
Aug 16, 1994·Proceedings of the National Academy of Sciences of the United States of America·J LisziewiczS Agrawal
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·N HijiyaA M Gewirtz
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·T SkorskiB Calabretta
Oct 1, 1996·Trends in Biotechnology·S Agrawal
Dec 1, 1961·Annals of Internal Medicine·S S KALTER

❮ Previous
Next ❯

Citations

Jan 6, 2000·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·M BertonR Gurny
Jan 5, 1999·Bioorganic & Medicinal Chemistry Letters·E R KandimallaS Agrawal
Apr 17, 1999·Bioorganic & Medicinal Chemistry Letters·M R Player, P F Torrence
Jul 18, 2000·Journal of the American College of Surgeons·D W GreenJ A Drebin
Feb 1, 2000·Molecular Medicine Today·S Agrawal, E R Kandimalla
Nov 13, 2001·Reviews in Clinical and Experimental Hematology·T Raife, R Montgomery
May 21, 1998·Antisense & Nucleic Acid Drug Development·S Agrawal, Q Zhao
May 29, 2015·Expert Opinion on Biological Therapy·Marina A Dobrovolskaia, Scott E McNeil
Apr 1, 2015·Nucleic Acid Therapeutics·Manuel SchmidtBurghardt Wittig
Oct 30, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Sara M MangsboThomas H Tötterman
Apr 28, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J S WatersF E Cotter
Jan 10, 2019·Journal for Immunotherapy of Cancer·Kerstin KappManuel Schmidt
Jul 17, 2020·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Marina A Dobrovolskaia, Mark Bathe
Oct 20, 2019·Journal of Controlled Release : Official Journal of the Controlled Release Society·Lisa MunakataTaiki Aoshi
Apr 9, 2021·Expert Review of Anticancer Therapy·Yizhen JinMei Liu
Nov 3, 2004·Toxicology and Applied Pharmacology·Tracey L H JasonRandal W Berg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.